Holkova, Beata <br/><br/>
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.  [electronic resource] 

 -  Leukemia & lymphoma  2016 
 - 635-43 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2015.1075019  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers<br/>Combined Modality Therapy<br/>Cytokines--blood<br/>Drug Monitoring<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Lymphoma, B-Cell--blood<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Oligopeptides--administration & dosage<br/>Retreatment<br/>Treatment Outcome<br/>Vorinostat